Ovid Therapeutics Inc
(FRA:1OT)
€
0.615
-0.045 (-6.82%)
Market Cap: 51.35 Mil
Enterprise Value: -18.30 Mil
PE Ratio: 0
PB Ratio: 0.70
GF Score: 32/100 - Ovid Therapeutics Inc To Host Research & Development (R&D) Day TranscriptOct 02, 2023
- Ovid Therapeutics Inc at Needham Healthcare Conference (Virtual) TranscriptApr 17, 2023
- Ovid Therapeutics Inc at Needham Healthcare Conference (Virtual) TranscriptApr 14, 2022
- Ovid Therapeutics Inc at Ladenburg Thalmann Virtual Healthcare Conference TranscriptJul 14, 2021
- Ovid Therapeutics Inc Annual Shareholders Meeting TranscriptJun 10, 2021
- Ovid Therapeutics Inc at RBC Capital Markets Global Healthcare Conference (Virtual) TranscriptMay 19, 2021
- Ovid Therapeutics Inc and Takeda Pharmaceutical Co Ltd to Discuss Strategic Transaction Call TranscriptMar 03, 2021
- Ovid Therapeutics Inc. - Special Call TranscriptOct 22, 2020
- Ovid Therapeutics Inc. - Special Call TranscriptAug 25, 2020
- Ovid Therapeutics Inc. - Special Call TranscriptJul 13, 2020
- Ovid Therapeutics Inc. - Special Call TranscriptJun 17, 2020
- Ovid Therapeutics Inc Annual Shareholders Meeting TranscriptJun 04, 2020
- Ovid Therapeutics to Discuss Positive Initial Data from Ongoing ENDYMION Trial Call TranscriptSep 23, 2019
- Ovid Therapeutics Inc. - Special Call TranscriptJun 27, 2019
Ovid Therapeutics Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript
May 19, 2021 / 01:10PM GMT
Release Date Price:
€3.08
(+4.05%)
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst
Good morning, everyone. I'm Brian Abrahams, senior biotech analyst here at RBC Capital Markets, and welcome again to day 2 of our healthcare conference.
Our next presenting company is Ovid Therapeutics, represented by their CEO and Chairman of the Board, Jeremy Levin. Jeremy thanks again for joining us.
Jeremy Max Levin
Ovid Therapeutics Inc. - Chairman & CEO
Brian, thanks a lot. Pleasure being here with you. Nice to see you at least on video. It'd be fun to see you face to face.
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst
Sure, would, hopefully soon.
Questions & Answers
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst
So a lot going on at Ovid these days. You recently closed your amended deal with Takeda. Can you maybe talk a little bit more about that and
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)